IDEXX Laboratories Financials

IDXX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows IDEXX Laboratories (IDXX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 74/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

IDEXX Laboratories has an operating margin of 31.6%, meaning the company retains $32 of operating profit per $100 of revenue. This strong profitability earns a score of 92/100, reflecting efficient cost management and pricing power. This is up from 28.9% the prior year.

Growth

IDEXX Laboratories's revenue grew 10.4% year-over-year to $4.3B, a solid pace of expansion. This earns a growth score of 51/100.

Leverage

IDEXX Laboratories carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

IDEXX Laboratories's current ratio of 1.23 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 20/100, which could limit financial flexibility.

Cash Flow

IDEXX Laboratories converts 24.6% of revenue into free cash flow ($1.1B). This strong cash generation earns a score of 86/100.

Returns

100

IDEXX Laboratories earns a strong 66.0% return on equity (ROE), meaning it generates $66 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 55.6% the prior year.

Altman Z-Score Safe

20.94

IDEXX Laboratories scores 20.94, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($45.2B) relative to total liabilities ($1.7B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

8/9

IDEXX Laboratories passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.12x

For every $1 of reported earnings, IDEXX Laboratories generates $1.12 in operating cash flow ($1.2B OCF vs $1.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

35.0x

IDEXX Laboratories earns $35.0 in operating income for every $1 of interest expense ($1.4B vs $38.9M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.3B

YoY+10.4%

5Y CAGR+9.7%

10Y CAGR+10.4%

IDEXX Laboratories generated $4.3B in revenue in fiscal year 2025. This represents an increase of 10.4% from the prior year.

EBITDA

$1.5B

YoY+19.6%

5Y CAGR+13.7%

10Y CAGR+15.1%

IDEXX Laboratories's EBITDA was $1.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.6% from the prior year.

Net Income

$1.1B

YoY+19.3%

5Y CAGR+12.7%

10Y CAGR+18.6%

IDEXX Laboratories reported $1.1B in net income in fiscal year 2025. This represents an increase of 19.3% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

$1.1B

YoY+30.8%

5Y CAGR+14.3%

10Y CAGR+22.5%

IDEXX Laboratories generated $1.1B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 30.8% from the prior year.

Cash & Debt

$180.1M

YoY-37.5%

5Y CAGR-14.1%

10Y CAGR+3.4%

IDEXX Laboratories held $180.1M in cash against $374.8M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

80M

YoY-2.1%

5Y CAGR-1.4%

10Y CAGR-1.2%

IDEXX Laboratories had 80M shares outstanding in fiscal year 2025. This represents a decrease of 2.1% from the prior year.

Margins & Returns

Gross Margin

61.8%

YoY+0.8pp

5Y CAGR+3.8pp

10Y CAGR+6.2pp

IDEXX Laboratories's gross margin was 61.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.8 percentage points from the prior year.

Operating Margin

31.6%

YoY+2.7pp

5Y CAGR+5.9pp

10Y CAGR+12.9pp

IDEXX Laboratories's operating margin was 31.6% in fiscal year 2025, reflecting core business profitability. This is up 2.7 percentage points from the prior year.

Net Margin

24.6%

YoY+1.8pp

5Y CAGR+3.1pp

10Y CAGR+12.6pp

IDEXX Laboratories's net profit margin was 24.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.8 percentage points from the prior year.

Return on Equity

66.0%

YoY+10.3pp

5Y CAGR-26.0pp

IDEXX Laboratories's ROE was 66.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 10.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$251.2M

YoY+14.3%

5Y CAGR+12.2%

10Y CAGR+9.7%

IDEXX Laboratories invested $251.2M in research and development in fiscal year 2025. This represents an increase of 14.3% from the prior year.

Share Buybacks

$1.2B

YoY+45.4%

5Y CAGR+46.1%

10Y CAGR+11.7%

IDEXX Laboratories spent $1.2B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 45.4% from the prior year.

Capital Expenditures

$124.7M

YoY+3.1%

5Y CAGR+3.1%

10Y CAGR+4.2%

IDEXX Laboratories invested $124.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3.1% from the prior year.

IDXX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$4.3B+10.4%	$3.9B+6.5%	$3.7B+8.7%	$3.4B+4.7%	$3.2B+18.8%	$2.7B
Cost of Revenue	$1.6B+8.3%	$1.5B+3.2%	$1.5B+7.9%	$1.4B+2.8%	$1.3B+16.8%	$1.1B
Gross Profit	$2.7B+11.8%	$2.4B+8.6%	$2.2B+9.3%	$2.0B+6.1%	$1.9B+20.3%	$1.6B
R&D Expenses	$251.2M+14.3%	$219.8M+15.1%	$191.0M-25.1%	$254.8M+58.3%	$161.0M+14.0%	$141.2M
SG&A Expenses	$404.8M-8.5%	$442.3M+31.7%	$335.8M+2.9%	$326.2M+5.4%	$309.7M+2.9%	$300.8M
Operating Income	$1.4B+20.5%	$1.1B+2.8%	$1.1B+22.1%	$898.8M-3.6%	$932.0M+34.2%	$694.5M
Interest Expense	$38.9M+24.5%	$31.2M-25.0%	$41.6M+4.3%	$39.9M+33.7%	$29.8M-10.0%	$33.1M
Income Tax	$264.7M+19.3%	$222.0M+2.7%	$216.1M+19.5%	$180.9M+14.6%	$157.8M+97.6%	$79.9M
Net Income	$1.1B+19.3%	$887.9M+5.1%	$845.0M+24.4%	$679.1M-8.8%	$744.8M+28.0%	$581.8M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.1B-1.3%	$1.1B-0.4%	$1.1B+11.1%	$998.4M+4.6%	$954.3M-2.2%	$975.5M-2.8%	$1.0B+4.1%	$964.1M
Cost of Revenue	$432.5M+2.5%	$421.9M+1.7%	$414.7M+10.6%	$375.0M-2.2%	$383.6M+1.1%	$379.5M-1.3%	$384.4M+3.6%	$371.0M
Gross Profit	$658.1M-3.7%	$683.4M-1.6%	$694.7M+11.4%	$623.4M+9.2%	$570.7M-4.3%	$596.0M-3.7%	$619.2M+4.4%	$593.1M
R&D Expenses	$66.8M+5.4%	$63.4M+2.5%	$61.9M+4.8%	$59.1M+2.3%	$57.7M+6.9%	$54.0M-2.7%	$55.5M+5.3%	$52.6M
SG&A Expenses	$108.6M+2.5%	$105.9M+7.4%	$98.7M+7.8%	$91.6M-9.5%	$101.1M+10.1%	$91.9M-41.6%	$157.2M+70.9%	$92.0M
Operating Income	$315.6M-11.1%	$354.8M-4.9%	$373.0M+17.9%	$316.5M+21.0%	$261.7M-13.9%	$303.9M+15.2%	$263.8M-11.8%	$299.0M
Interest Expense	$9.2M-13.6%	$10.7M-5.9%	$11.3M+47.7%	$7.7M+2.2%	$7.5M-2.6%	$7.7M-5.0%	$8.1M+2.4%	$7.9M
Income Tax	$58.8M-16.2%	$70.2M+2.6%	$68.4M+1.4%	$67.4M+67.5%	$40.2M-39.1%	$66.1M+18.5%	$55.8M-6.9%	$59.9M
Net Income	$248.2M-9.6%	$274.6M-6.6%	$294.0M+21.1%	$242.7M+12.3%	$216.1M-7.2%	$232.8M+14.5%	$203.3M-13.7%	$235.6M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IDXX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$3.4B+1.7%	$3.3B+1.0%	$3.3B+18.7%	$2.7B+12.7%	$2.4B+6.2%	$2.3B
Current Assets	$1.4B+1.0%	$1.4B-6.4%	$1.5B+35.7%	$1.1B+15.3%	$955.7M-10.1%	$1.1B
Cash & Equivalents	$180.1M-37.5%	$288.3M-36.5%	$453.9M+303.3%	$112.5M-22.1%	$144.5M-62.4%	$383.9M
Inventory	$377.8M-1.1%	$381.9M+0.4%	$380.3M+3.4%	$367.8M+36.7%	$269.0M+28.2%	$209.9M
Accounts Receivable	$552.4M+16.6%	$473.6M+3.5%	$457.4M+14.2%	$400.6M+8.8%	$368.3M+11.1%	$331.4M
Goodwill	$414.0M+2.2%	$405.1M+10.7%	$366.0M+1.2%	$361.8M+0.7%	$359.3M+47.7%	$243.3M
Total Liabilities	$1.7B+2.8%	$1.7B-4.4%	$1.8B-17.0%	$2.1B+22.4%	$1.7B+5.1%	$1.7B
Current Liabilities	$1.1B+7.6%	$1.1B+12.2%	$951.5M-23.0%	$1.2B+61.8%	$763.6M+31.0%	$582.8M
Long-Term Debt	$374.8M-16.7%	$449.8M-27.8%	$622.9M-10.3%	$694.4M-10.4%	$775.2M-9.7%	$858.5M
Total Equity	$1.6B+0.6%	$1.6B+7.5%	$1.5B+143.9%	$608.7M-11.8%	$690.0M+9.2%	$632.1M
Retained Earnings	$6.4B+19.9%	$5.3B+20.0%	$4.4B+23.5%	$3.6B+23.3%	$2.9B+34.2%	$2.2B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$3.4B-1.1%	$3.4B+1.7%	$3.3B+3.6%	$3.2B-2.4%	$3.3B-1.7%	$3.4B-1.9%	$3.4B+1.8%	$3.4B
Current Assets	$1.4B-4.3%	$1.5B+8.4%	$1.4B+3.4%	$1.3B-5.9%	$1.4B-2.4%	$1.4B-6.2%	$1.5B+1.8%	$1.5B
Cash & Equivalents	$180.1M-13.5%	$208.2M+26.5%	$164.6M+0.4%	$164.0M-43.1%	$288.3M-6.6%	$308.6M-23.1%	$401.6M+1.0%	$397.4M
Inventory	$377.8M-3.5%	$391.6M-0.3%	$392.6M-0.9%	$396.0M+3.7%	$381.9M-2.0%	$389.8M+2.6%	$380.0M-2.7%	$390.6M
Accounts Receivable	$552.4M-2.6%	$566.9M+1.1%	$560.6M+6.3%	$527.5M+11.4%	$473.6M-7.4%	$511.3M-4.2%	$533.6M+5.2%	$507.2M
Goodwill	$414.0M+0.1%	$413.7M-0.2%	$414.5M+1.7%	$407.5M+0.6%	$405.1M-1.7%	$412.1M+1.0%	$408.0M-0.2%	$408.7M
Total Liabilities	$1.7B-4.4%	$1.8B-2.5%	$1.9B+6.0%	$1.8B+4.0%	$1.7B-2.0%	$1.7B-5.6%	$1.8B+2.8%	$1.8B
Current Liabilities	$1.1B-8.2%	$1.3B+2.3%	$1.2B+7.7%	$1.1B+6.4%	$1.1B+5.8%	$1.0B-9.6%	$1.1B+16.7%	$956.9M
Long-Term Debt	$374.8M0.0%	$374.8M-16.7%	$449.8M0.0%	$449.8M0.0%	$449.8M-14.3%	$524.8M0.0%	$524.7M-15.5%	$620.8M
Total Equity	$1.6B+2.8%	$1.6B+7.0%	$1.5B+0.7%	$1.4B-9.2%	$1.6B-1.4%	$1.6B+2.4%	$1.6B+0.7%	$1.6B
Retained Earnings	$6.4B+4.0%	$6.1B+4.7%	$5.9B+5.3%	$5.6B+4.6%	$5.3B+4.2%	$5.1B+4.8%	$4.9B+4.3%	$4.7B

IDXX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.2B+27.2%	$929.0M+2.5%	$906.5M+66.9%	$543.0M-28.1%	$755.5M+16.6%	$648.1M
Capital Expenditures	$124.7M+3.1%	$120.9M-9.5%	$133.6M-10.2%	$148.8M+24.5%	$119.5M+11.8%	$107.0M
Free Cash Flow	$1.1B+30.8%	$808.1M+4.6%	$772.9M+96.1%	$394.1M-38.0%	$636.0M+17.5%	$541.1M
Investing Cash Flow	-$136.2M+34.2%	-$207.1M-65.3%	-$125.3M+35.9%	-$195.3M+33.3%	-$293.0M-167.9%	-$109.4M
Financing Cash Flow	-$1.2B-32.7%	-$878.1M-98.7%	-$442.0M-19.2%	-$370.9M+46.8%	-$697.4M-180.7%	-$248.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$1.2B+45.4%	$837.0M+1063.8%	$71.9M-91.2%	$819.7M+9.8%	$746.8M+308.5%	$182.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$355.8M-11.6%	$402.3M+116.6%	$185.7M-21.9%	$238.0M-9.2%	$262.0M+19.1%	$220.1M-11.4%	$248.3M+25.0%	$198.6M
Capital Expenditures	$29.4M-5.4%	$31.1M-8.8%	$34.1M+13.6%	$30.0M+2.6%	$29.3M+4.2%	$28.1M-15.7%	$33.3M+10.0%	$30.3M
Free Cash Flow	$326.3M-12.1%	$371.2M+144.8%	$151.6M-27.1%	$207.9M-10.7%	$232.8M+21.2%	$192.0M-10.7%	$215.0M+27.7%	$168.3M
Investing Cash Flow	-$28.1M+37.3%	-$44.9M-33.4%	-$33.6M-13.6%	-$29.6M+25.7%	-$39.8M-45.6%	-$27.4M+16.8%	-$32.9M+69.2%	-$106.9M
Financing Cash Flow	-$355.7M-13.5%	-$313.3M-89.2%	-$165.6M+49.9%	-$330.3M-41.9%	-$232.8M+20.0%	-$291.0M-38.4%	-$210.2M-45.9%	-$144.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$237.8M-1.0%	$240.2M-29.0%	$338.1M-15.7%	$400.9M+63.0%	$246.0M+11.4%	$220.8M+2.4%	$215.5M+39.3%	$154.8M

IDXX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	61.8%+0.8pp	61.0%+1.2pp	59.8%+0.3pp	59.5%+0.8pp	58.8%+0.7pp	58.0%
Operating Margin	31.6%+2.7pp	28.9%-1.0pp	30.0%+3.3pp	26.7%-2.3pp	29.0%+3.3pp	25.7%
Net Margin	24.6%+1.8pp	22.8%-0.3pp	23.1%+2.9pp	20.2%-3.0pp	23.2%+1.7pp	21.5%
Return on Equity	66.0%+10.3pp	55.6%-1.3pp	56.9%-54.6pp	111.6%+3.6pp	107.9%+15.9pp	92.0%
Return on Assets	31.6%+4.7pp	27.0%+1.0pp	25.9%+1.2pp	24.7%-5.8pp	30.6%+5.2pp	25.4%
Current Ratio	1.23-0.1	1.31-0.3	1.57+0.7	0.89-0.4	1.25-0.6	1.82
Debt-to-Equity	0.23-0.0	0.28-0.1	0.42-0.7	1.14+0.0	1.12-0.2	1.36
FCF Margin	24.6%+3.8pp	20.7%-0.4pp	21.1%+9.4pp	11.7%-8.1pp	19.8%-0.2pp	20.0%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	60.4%-1.5pp	61.8%-0.8pp	62.6%+0.2pp	62.4%+2.6pp	59.8%-1.3pp	61.1%-0.6pp	61.7%+0.2pp	61.5%
Operating Margin	28.9%-3.2pp	32.1%-1.5pp	33.6%+1.9pp	31.7%+4.3pp	27.4%-3.7pp	31.1%+4.9pp	26.3%-4.7pp	31.0%
Net Margin	22.8%-2.1pp	24.9%-1.7pp	26.5%+2.2pp	24.3%+1.7pp	22.7%-1.2pp	23.9%+3.6pp	20.3%-4.2pp	24.4%
Return on Equity	15.5%-2.1pp	17.6%-2.6pp	20.2%+3.4pp	16.8%+3.2pp	13.6%-0.8pp	14.4%+1.5pp	12.9%-2.2pp	15.0%
Return on Assets	7.4%-0.7pp	8.1%-0.7pp	8.8%+1.3pp	7.5%+1.0pp	6.6%-0.4pp	7.0%+1.0pp	5.9%-1.1pp	7.0%
Current Ratio	1.23+0.1	1.18+0.1	1.11-0.0	1.16-0.2	1.31-0.1	1.42+0.1	1.37-0.2	1.57
Debt-to-Equity	0.230.0	0.24-0.1	0.310.0	0.31+0.0	0.28-0.0	0.320.0	0.33-0.1	0.40
FCF Margin	29.9%-3.7pp	33.6%+19.9pp	13.7%-7.2pp	20.8%-3.6pp	24.4%+4.7pp	19.7%-1.7pp	21.4%+4.0pp	17.5%

Similar Companies

Agilent Technologies Inc A

$32.6B

Iqvia Hldgs Inc IQV

$29.1B

Mettler-Toledo MTD

$25.5B

Labcorp Holdings Inc LH

$22.6B

Natera Inc NTRA

$29.5B

Frequently Asked Questions

What is IDEXX Laboratories's annual revenue?

IDEXX Laboratories (IDXX) reported $4.3B in total revenue for fiscal year 2025. This represents a 10.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is IDEXX Laboratories's revenue growing?

IDEXX Laboratories (IDXX) revenue grew by 10.4% year-over-year, from $3.9B to $4.3B in fiscal year 2025.

Is IDEXX Laboratories profitable?

Yes, IDEXX Laboratories (IDXX) reported a net income of $1.1B in fiscal year 2025, with a net profit margin of 24.6%.

What is IDEXX Laboratories's EBITDA?

IDEXX Laboratories (IDXX) had EBITDA of $1.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does IDEXX Laboratories have?

As of fiscal year 2025, IDEXX Laboratories (IDXX) had $180.1M in cash and equivalents against $374.8M in long-term debt.

What is IDEXX Laboratories's gross margin?

IDEXX Laboratories (IDXX) had a gross margin of 61.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is IDEXX Laboratories's operating margin?

IDEXX Laboratories (IDXX) had an operating margin of 31.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is IDEXX Laboratories's net profit margin?

IDEXX Laboratories (IDXX) had a net profit margin of 24.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is IDEXX Laboratories's return on equity (ROE)?

IDEXX Laboratories (IDXX) has a return on equity of 66.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is IDEXX Laboratories's free cash flow?

IDEXX Laboratories (IDXX) generated $1.1B in free cash flow during fiscal year 2025. This represents a 30.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is IDEXX Laboratories's operating cash flow?

IDEXX Laboratories (IDXX) generated $1.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are IDEXX Laboratories's total assets?

IDEXX Laboratories (IDXX) had $3.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are IDEXX Laboratories's capital expenditures?

IDEXX Laboratories (IDXX) invested $124.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does IDEXX Laboratories spend on research and development?

IDEXX Laboratories (IDXX) invested $251.2M in research and development during fiscal year 2025.

Does IDEXX Laboratories buy back shares?

Yes, IDEXX Laboratories (IDXX) spent $1.2B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does IDEXX Laboratories have outstanding?

IDEXX Laboratories (IDXX) had 80M shares outstanding as of fiscal year 2025.

What is IDEXX Laboratories's current ratio?

IDEXX Laboratories (IDXX) had a current ratio of 1.23 as of fiscal year 2025, which is considered adequate.

What is IDEXX Laboratories's debt-to-equity ratio?

IDEXX Laboratories (IDXX) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is IDEXX Laboratories's return on assets (ROA)?

IDEXX Laboratories (IDXX) had a return on assets of 31.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is IDEXX Laboratories's Altman Z-Score?

IDEXX Laboratories (IDXX) has an Altman Z-Score of 20.94, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is IDEXX Laboratories's Piotroski F-Score?

IDEXX Laboratories (IDXX) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are IDEXX Laboratories's earnings high quality?

IDEXX Laboratories (IDXX) has an earnings quality ratio of 1.12x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can IDEXX Laboratories cover its interest payments?

IDEXX Laboratories (IDXX) has an interest coverage ratio of 35.0x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is IDEXX Laboratories?

IDEXX Laboratories (IDXX) scores 74 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.